Samuel William, Kutty R Krishnan, Nagineni Sahrudaya, Vijayasarathy Camasamudram, Chandraratna Roshantha A S, Wiggert Barbara
Biochemistry Section, Laboratory of Retinal Cell and Molecular Biology, National Eye Institute, 7 Memorial Drive, Bethesda, MD 20892, USA.
J Cell Physiol. 2006 Dec;209(3):854-65. doi: 10.1002/jcp.20774.
N-(4-hydroxyphenyl)retinamide (4HPR, fenretinide), a retinoic acid (RA) derivative and a potential cancer preventive agent, is known to exert its chemotherapeutic effects in cancer cells through induction of apoptosis. Earlier work from our laboratory has shown that relatively low concentrations of 4HPR induce neuronal differentiation of cultured human retinal pigment epithelial (ARPE-19) cells (Chen et al., 2003, J Neurochem 84:972-981). However, at higher concentrations of 4HPR, these cells showed morphological changes including cell shrinkage and cell death. Here we demonstrate that ARPE-19 cells treated with 4HPR exhibit a dose- and time-dependent induction of apoptosis as evidenced by morphological changes, mono- and oligonucleosome generation, and increased activity of caspases 2 and 3. The 4HPR-induced apoptosis as well as the activation of caspases 2 and 3 were blocked by both retinoic acid receptors (RAR) pan-antagonists, AGN193109 and AGN194310, and by an RARalpha-specific antagonist AGN194301. 4HPR treatment also increased reactive oxygen species (ROS) generation in ARPE-19 cells in a time-dependent manner as determined from the oxidation of 2',7'-dichlorofluorescin. In addition, the increase in the expression of heme oxygenase-1 (HO-1), a stress response protein, and the growth arrest and DNA damage-inducible transcription factor 153 (Gadd153) in response to the ROS generation were also blocked by these receptor antagonists. Pyrrolidine dithiocarbamate (PDTC), a free-radical scavenger, inhibited 4HPR-induced ROS generation, the expression of its downstream mediator, Gadd153, and apoptosis in the pretreated cells. Therefore, our results, clearly demonstrate that 4HPR induces apoptosis in ARPE-19 cells and that RARs mediate this process by regulating ROS generation as well as the expression of Gadd153 and HO-1.
N-(4-羟基苯基)视黄酰胺(4HPR,芬维A胺)是一种维甲酸(RA)衍生物,也是一种潜在的癌症预防剂,已知它通过诱导细胞凋亡在癌细胞中发挥其化疗作用。我们实验室早期的研究表明,相对较低浓度的4HPR可诱导培养的人视网膜色素上皮(ARPE-19)细胞发生神经元分化(Chen等人,2003年;《神经化学杂志》84:972 - 981)。然而,在较高浓度的4HPR作用下,这些细胞会出现形态变化,包括细胞收缩和细胞死亡。在此我们证明,用4HPR处理的ARPE-19细胞呈现出剂量和时间依赖性的细胞凋亡诱导,这可通过形态变化、单核小体和寡核小体的产生以及半胱天冬酶2和3活性的增加来证明。视黄酸受体(RAR)泛拮抗剂AGN193109和AGN194310以及RARα特异性拮抗剂AGN194301均可阻断4HPR诱导的细胞凋亡以及半胱天冬酶2和3的激活。4HPR处理还以时间依赖性方式增加了ARPE-19细胞中活性氧(ROS)的产生,这是通过2',7'-二氯荧光素的氧化来测定的。此外,这些受体拮抗剂也阻断了应激反应蛋白血红素加氧酶-1(HO-1)以及生长停滞和DNA损伤诱导转录因子153(Gadd153)因ROS产生而导致的表达增加。自由基清除剂吡咯烷二硫代氨基甲酸盐(PDTC)可抑制4HPR诱导的ROS产生、其下游介质Gadd153的表达以及预处理细胞中的细胞凋亡。因此,我们的结果清楚地表明,4HPR可诱导ARPE-19细胞凋亡,并且RARs通过调节ROS产生以及Gadd153和HO-1的表达来介导这一过程。